Laboratory Corporation of America stock price target raised to $323 at Leerink

Published 24/07/2025, 19:24
Laboratory Corporation of America stock price target raised to $323 at Leerink

Investing.com - Leerink Partners has raised its price target on Laboratory Corporation of America (NYSE:LH) to $323.00 from $293.00 while maintaining an Outperform rating on the stock. The stock, currently trading at $267.46, has shown strong momentum with a 21% return over the past year and is currently trading near its 52-week high, according to InvestingPro data.

The price target increase follows what Leerink described as "an impressive large-cap pharma services earnings season" for Labcorp, with strength demonstrated across its diagnostics business and biopharma laboratory services (BLS) division. This performance is reflected in the company’s solid 7.13% revenue growth and robust financial health score of GOOD on InvestingPro, which offers 8 additional key insights about the company’s performance.

Leerink identified several durable factors contributing to Labcorp’s performance, including tests per accession, specialty testing, and increased clinical trial and drug discovery activity, which bolstered the firm’s confidence in LH’s fundamentals through the second half of the year and into 2026.

The research firm acknowledged potential headwinds facing Labcorp, including PAMA, Medicaid, and HIX, but characterized these challenges as either immaterial or transitory, and unlikely to derail the company’s key growth drivers.

Leerink’s new price target is based on approximately 18.0x CY26E EPS, up from 16.5x previously, which the firm noted is in line with its target multiple for Quest Diagnostics (NYSE:DGX) given similar or better reported organic growth and improvement within Labcorp’s BLS segment.

In other recent news, Labcorp Holdings Inc. reported strong financial results for the second quarter of 2025. The company exceeded analysts’ expectations with an adjusted earnings per share (EPS) of $4.35, surpassing the forecasted $4.17. Labcorp also outperformed revenue projections, recording $3.53 billion compared to the anticipated $3.48 billion. These results reflect a positive performance for the company. The earnings announcement has been a significant development for Labcorp, drawing attention from investors. While the stock’s movement post-announcement isn’t covered here, the financial metrics indicate a robust quarter for the company. Investors and analysts will likely be watching Labcorp closely following these results.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.